Literature DB >> 15917201

RASA1: variable phenotype with capillary and arteriovenous malformations.

Laurence M Boon1, John B Mulliken, Miikka Vikkula.   

Abstract

Capillary malformation-arteriovenous malformation (CM-AVM) is a newly discovered hereditary disorder. Its defining features are atypical cutaneous multifocal capillary malformations often in association with high-flow lesions: cutaneous, subcutaneous, intramuscular, intraosseous and cerebral arteriovenous malformations and arteriovenous fistulas. Some patients have Parkes Weber syndrome - a large congenital cutaneous vascular stain in an extremity, with bony and soft tissue hypertrophy and microscopic arteriovenous shunting. In the past, arteriovenous malformations and arteriovenous fistulas had been considered non-hereditary. A classical genetic approach was used to identify the locus. Candidate gene screening pinpointed mutations in RASA1 (p120-RASGAP) - a RasGTPase. RASA1 reverts active GTP-bound Ras into inactive GDP-bound form. Murine Rasa1 knockout and tetraploid-aggregated embryos with RNA interference exhibited abnormal vascular development. Lack of RASA1 activity caused inhibition of cell motility, possibly through p190-RhoGAP. Thus, RASA1 defects probably cause abnormal angiogenic remodeling of the primary capillary plexus that cannot be compensated for by other RasGAPs: RASA2, RASAL and NF1. Signaling pathways involving RASA1 might offer novel targets for treatment of high-flow vascular anomalies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917201     DOI: 10.1016/j.gde.2005.03.004

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  63 in total

1.  Turning on the angiogenic microswitch.

Authors:  Hanna M Eilken; Ralf H Adams
Journal:  Nat Med       Date:  2010-08       Impact factor: 53.440

Review 2.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

3.  From blue jeans to blue genes.

Authors:  Laurence M Boon; Miikka Vikkula
Journal:  J Craniofac Surg       Date:  2009-03       Impact factor: 1.046

Review 4.  From germline towards somatic mutations in the pathophysiology of vascular anomalies.

Authors:  Nisha Limaye; Laurence M Boon; Miikka Vikkula
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

5.  Lymphatic abnormalities are associated with RASA1 gene mutations in mouse and man.

Authors:  Patricia E Burrows; Manuel L Gonzalez-Garay; John C Rasmussen; Melissa B Aldrich; Renie Guilliod; Erik A Maus; Caroline E Fife; Sunkuk Kwon; Philip E Lapinski; Philip D King; Eva M Sevick-Muraca
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 6.  Laser and IPL treatment of port-wine stains: therapy options, limitations, and practical aspects.

Authors:  Annette Klein; Wolfgang Bäumler; Michael Landthaler; Philipp Babilas
Journal:  Lasers Med Sci       Date:  2011-03-10       Impact factor: 3.161

7.  The associations of two SNPs in miRNA-146a and one SNP in ZBTB38-RASA2 with the disease susceptibility and the clinical features of the Chinese patients of sCJD and FFI.

Authors:  Chen Gao; Qiang Shi; Jing Wei; Wei Zhou; Kang Xiao; Jing Wang; Qi Shi; Xiao-Ping Dong
Journal:  Prion       Date:  2018-01-02       Impact factor: 3.931

8.  A novel association between RASA1 mutations and spinal arteriovenous anomalies.

Authors:  R Thiex; J B Mulliken; N Revencu; L M Boon; P E Burrows; M Cordisco; Y Dwight; E R Smith; M Vikkula; D B Orbach
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-10       Impact factor: 3.825

Review 9.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 10.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.